Neogen Chemicals subsidiary issues ₹76.80 crore shares to Morita
- Neogen Morita New Materials issued 7,20,000 equity shares at ₹1,066.66 each
- Total aggregate amount raised is ₹76.80 crore from Morita Investment Limited
- Morita Investment Limited acquires a 9.09% stake post-allotment
- Transaction follows the Joint Venture Agreement dated August 31, 2025
*this image is generated using AI for illustrative purposes only.
Neogen Chemicals Limited announced that its step-down subsidiary, Neogen Morita New Materials Limited (NML), has approved a preferential issue of equity shares worth ₹76.80 crore to Morita Investment Limited (MIL).
The Board of Directors of NML approved the issuance of 7,20,000 equity shares at a price of ₹1,066.66 per share on September 26, 2026. This transaction is executed in accordance with the Joint Venture Agreement signed between Neogen Ionics Limited and MIL on August 31, 2025.
Transaction Structure
The preferential allotment involves a single allottee, Morita Investment Limited, which is a wholly owned subsidiary of Morita Chemicals Industries Co. Limited (MCL). The issue price includes a premium of ₹1,056.66 per share over the face value of ₹10.
The transaction remains subject to approval from the members of Neogen Chemicals Limited and other requisite statutory and regulatory clearances. As NML is an unlisted public limited company, SEBI ICDR Regulations lock-in requirements do not apply.
Post-Allotment Holdings
The issuance dilutes the existing holding structure by introducing MIL as a non-promoter public shareholder. Prior to this allotment, MIL held no equity in NML.
| Particulars | Details |
|---|---|
| Total Shares Issued | 7,20,000 |
| Issue Price | ₹1,066.66 |
| Aggregate Amount | ₹76.80 crore |
| Allottee | Morita Investment Limited |
| Pre-Allotment Holding | 0% |
| Post-Allotment Holding | 9.09% |
Strategic Implications
The entry of Morita Investment Limited marks a significant step in the joint venture between Neogen Ionics Limited and MCL. By acquiring a 9.09% stake in NML, MIL strengthens its operational and financial alignment with the subsidiary. The capital infusion supports the strategic objectives outlined in the August 2025 Joint Venture Agreement.
Historical Stock Returns for Neogen Chemicals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.54% | -0.43% | +11.84% | +92.74% | +55.25% | +90.50% |
How will the ₹76.80 crore capital infusion specifically accelerate the production capacity or R&D timelines for Neogen Morita New Materials?
What are the anticipated financial impacts on Neogen Chemicals' consolidated earnings once the joint venture with Morita Chemicals reaches operational scale?
Does the 9.09% stake held by Morita Investment Limited grant it any board representation or veto rights that could influence future strategic decisions at NML?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
